Sugi Predict

Sugi Predict / Compounds / SCHEMBL6699326

SCHEMBL6699326

SCHEMBL6699326

O=C1CCC2(CC1)Cn1cc(C(=O)NCc3ccc(Cl)cc3)c(=S)c3cc(CN4CCOCC4)cc(c31)O2

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 2/20 0.52
▸ KCNH2 Q12809 7/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ ENPP2 Q13822 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ F2 P00734 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6698535 0.94 POLA1 (0.53) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL6697411 0.93 POLA1 (0.54) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL6702953 0.93 POLA1 (0.61) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL6696093 0.91 POLA1 (0.51) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL6699084 0.91 POLA1 (0.51) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL6698378 0.91 POLA1 (0.50) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL7026902 0.89 POLA1 (0.51) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL6693371 0.87 POLA1 (0.64) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL6699282 0.87 POLA1 (0.54) POLA1KCNH2RXFP1ALDH1A1ENPP2
SCHEMBL6697957 0.87 POLA1 (0.53) POLA1KCNH2RXFP1ALDH1A1ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186131-A1 Method of preventing or treating atherosclerosis or restenosis WATHEN MICHAEL W 2004-09-23 — — US claimed
EP-1299395-B1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS UPJOHN CO (US) 2004-09-15 — — EP claimed
US-6673793-B2 N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY PHARMACIA & UPJOHN CO. 2004-01-06 — — US claimed
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections PHARMACIA & UPJOHN COMPANY 2002-08-01 — — US claimed
EP-1299395-B1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS UPJOHN CO (US) 2004-09-15 — — EP disclosed
US-6673793-B2 N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY PHARMACIA & UPJOHN CO. 2004-01-06 — — US disclosed
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections PHARMACIA & UPJOHN COMPANY 2002-08-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186131-A1 Method of preventing or treating atherosclerosis or restenosis LDLR, NR1H3, NR1H2 POLA1 2550/4885KCNH2 4383/4885RXFP1 45/4885
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections ZC3HAV1, RPL5, ZC3HAV1L POLA1 111/4885KCNH2 964/4885RXFP1 4210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.